PA
IONS icon

Perceptive Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Perceptive Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-60,000
Closed -$24K – 144
2017
Q3 		$24K Buy
+60,000
New +$3.14M ﹤0.01% 139

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Perceptive Advisors's IONS Position: Q2 2026 in Review

Perceptive Advisors increased its Ionis Pharmaceuticals (IONS) stake by 12% in Q2 2026, buying an estimated $4.67M and bringing the position to 566,000 shares worth $44.9M. The position accounts for 0.67% of the portfolio, ranked #32.

Perceptive Advisors first reported a position in IONS in Q3 2013 and has held it in 3 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Perceptive Advisors held 566,000 shares of Ionis Pharmaceuticals worth $44.9M as of Q2 2026.
  • Perceptive Advisors bought 62,000 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.67M.
  • Ionis Pharmaceuticals made up 0.67% of Perceptive Advisors's portfolio in Q2 2026, its #32 holding.
  • Perceptive Advisors first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.